Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis

2012 ◽  
Vol 33 (3) ◽  
pp. 265-274 ◽  
Author(s):  
Edward J. Meier ◽  
Gail L. Torkildsen ◽  
James A. Gow ◽  
Timothy R. McNamara ◽  
Paul J. Gomes ◽  
...  
Keyword(s):  
Allergic Conjunctivitis ◽  
Ophthalmic Solution ◽  
Phase Iii ◽  
Ocular Itching ◽  
Phase Iii Trials

Icodextrin Peritoneal Dialysis Solution

2003 ◽  
Vol 38 (7) ◽  
pp. 669-678
Author(s):  
Dennis J. Cada ◽  
Terri Levien ◽  
Danial E. Baker
Keyword(s):  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Ophthalmic Solution ◽  
Phase Iii ◽  
Bulletin Board ◽  
Target Drug ◽  
Dialysis Solution ◽  
Phase Iii Trials ◽  
Peritoneal Dialysis Solution

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800–322–4349. The June 2003 monograph topics are aprepitant, gemifloxacin, desirudin for injection, gatifloxacin ophthalmic solution, and pegvisomant. The DUE is on aprepitant.

The Expanding Picture of the Clinical Utility of BEPREVE® (Bepotastine Besilate Ophthalmic Solution) 1.5 % in the Treatment of Itch Associated with Allergic Conjunctivitis

2011 ◽  
Vol 04 (02) ◽  
pp. 101
Author(s):  
Richard L Lindstrom ◽  
Keyword(s):  
Allergic Conjunctivitis ◽  
Clinical Utility ◽  
Therapeutic Response ◽  
Ophthalmic Solution ◽  
Trial Data ◽  
Ocular Allergy ◽  
Pivotal Trial ◽  
Exposure Study ◽  
Fda Approval ◽  
Ocular Itching

A new analysis of pivotal trial data and a variety of additional studies completed since US Food and Drug Administration (FDA) approval are broadening our understanding of the clinical utility of BEPREVE® (bepotastine besilate ophthalmic solution) 1.5 % in the treatment of ocular itch associated with allergic conjunctivitis. These results include evidence of a durable therapeutic response of up to 16 hours following a single dose, a comfort profile comparable or superior to other drugs in the class, and robust efficacy against ocular itching and redness in an environmental exposure study model that simulates the patient experience of ocular allergy.

Aprepitant

2003 ◽  
Vol 38 (8) ◽  
pp. 763-774 ◽  
Author(s):  
Dennis J. Cada ◽  
Terri Levien ◽  
Danial E. Baker
Keyword(s):  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Ophthalmic Solution ◽  
Phase Iii ◽  
Bulletin Board ◽  
Pharmacy And Therapeutics Committee ◽  
Target Drug ◽  
Phase Iii Trials ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800–322–4349. The June 2003 monograph topics are aprepitant, gemifloxacin, desirudin for injection, gatifloxacin ophthalmic solution, and pegvisomant. The DUE is on aprepitant.

Allergic inflammation of the anterior surface of the eye

2020 ◽  
Vol 41 (6) ◽  
pp. 449-453 ◽  
Author(s):  
Leonard Bielory
Keyword(s):  
Allergic Conjunctivitis ◽  
Allergic Inflammation ◽  
Tear Film ◽  
Ophthalmic Solution ◽  
Histamine Receptor ◽  
Oral Medications ◽  
Ocular Itching ◽  
Repurposed Drugs ◽  
New Treatments ◽  
H1 Receptor Antagonist

Background: Ocular allergies affect an estimated 40% of the population, 98% of which are because of allergic conjunctivitis and includes tear film dysfunction. With the current advent of both repurposed drugs for ocular allergies, as well as novel drugs, lubricants and methods of administration, there is a need to update new treatments to optimize the care of ocular allergy patients. Methods: An overview of mediators, clinical characteristics and management is provided in a summary format. Results: Lubricants (best when refrigerated provide immediate relief that is short lived (several minutes) due to its dilutional effect on mediators and pollen in the tear film. Immediate and longer-term benefit occurs from different topical and oral medications ‐ primarily histamine receptor agonists. Conclusion: The newest prescription topical ophthalmic histamine H1 receptor antagonist (an inverse agonist) to be approved by the U.S. Food and Drug Administration in the past 10 years (U.S. NDA approved May 30, 2017) is cetirizine ophthalmic solution for the treatment of ocular itching with allergic conjunctivitis in adults and in children more than 2 years old.

Oseltamivir

2000 ◽  
Vol 35 (3) ◽  
pp. 275-285
Author(s):  
Dennis J. Cada ◽  
Danial E. Baker ◽  
Terri Levien
Keyword(s):  
Information Exchange ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Ophthalmic Solution ◽  
Phase Iii ◽  
Bulletin Board ◽  
Pharmacy And Therapeutics Committee ◽  
Target Drug ◽  
Phase Iii Trials ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary® Monograph Service receive five to six researched monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board called The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The February 2000 Formulary monographs are dofetilide, bexarotine, dexmedetomidine HCl, nitric oxide for inhalation, and nedocromil sodium ophthalmic solution. The DUE is on doeftilide.

Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Ocular Itching in a Clinical Model of Allergic Conjunctivitis

2009 ◽  
Vol 123 (2) ◽  
pp. S57-S57 ◽  
Author(s):  
G.L. Torkildsen ◽  
P.J. Gomes ◽  
J.I. Williams ◽  
J.A. Gow ◽  
T.R. McNamara
Keyword(s):  
Allergic Conjunctivitis ◽  
Ophthalmic Solution ◽  
Clinical Model ◽  
Ocular Itching
Sign in / Sign up

Export Citation Format

Share Document